# Maximus review 2026: the men's performance-medicine play, examined

> Source: https://peptidewellnessusa.com/providers/maximus/
> Provider review · Premium DTC (men's hormone) · 2026
> By PeptideWellness Editorial Team · Updated November 11, 2026

Testosterone, not weight loss, is the core of Maximus, and it describes its medical advisers as urology faculty at Tulane, Cedars-Sinai and UNC. The compounded GLP-1 line is secondary; the proprietary oxytocin cream and the off-label enclomiphene protocols are the company's distinctive bets. We pulled the live entry pricing, checked the named advisers against the NPI Registry, and weighed the self-published whitepaper layer against the peer-reviewed evidence base honestly.

**The short version.** Maximus is the only provider in our set with testosterone as its primary category. The platform offers testosterone in four formats — cream, injectable, oral, and enclomiphene — alongside a GLP-1 weight-loss line, a patent-pending oxytocin "calming cream" for mood and stress, and growth-hormone peptides. Maximus describes its medical advisory board as a Chief of Andrology at Tulane Medical Center, a Cedars-Sinai urology faculty member and adjunct faculty at UNC's urology department; the four advisers we could match are active in the NPI Registry.

The main trade-offs are that the platform leans heavily on self-published whitepapers as evidence for its protocols (none of which clear our independent-evidence bar), that enclomiphene as TRT is off-label and not foregrounded as such, and that the company-stated outcome visualizations ("3.1× free testosterone," "28% body fat reduction") are presented in chart format without any peer-reviewed footnote. Best if you want a testosterone-focused platform with a named medical advisory board; skip it if you want only FDA-approved therapies, peer-reviewed evidence for marketing claims, or detailed transparency on the compounded GLP-1 line. One more thing to know: the CEO and co-founder is presented as "Dr." on the strength of a PhD in clinical psychology, not a medical degree.

> "A named advisory board that checks out in the NPI Registry, paired with a marketing layer that leans on self-published whitepapers and uncited outcome visualizations." — Editorial on Maximus

**Update — June 18, 2026.** On June 16 the FDA posted a [warning letter to Maximus Health, Inc.](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026 "Source — FDA Warning Letter MARCS-CMS 730095, June 8 2026") dated June 8, 2026, citing four phrases on the Maximus weight-loss page as false or misleading under sections 502(a) and 502(bb) of the FD&C Act: "Clinically studied ingredients," "Clinically studied to help patients…," "Proven to lose weight effectively," and a description of the source as "FDA approved pharmacies."

All four phrases are exactly the kind of language our review's source-hierarchy framework already discounts as company-self-reported (Tier C). The letter gives Maximus fifteen business days from receipt to respond — a window that closed at the end of June 2026.

We cover the full enforcement wave (eight telehealth letters in the same batch) in our [news story on the June 2026 FDA action](https://peptidewellnessusa.com/news/fda-warning-letters-compounded-glp-1-june-2026/). **Re-checked 15 October 2026:** none of the four phrases is on the [weight-loss page](https://www.maximustribe.com/weight-loss "Source — Maximus, weight-loss page, read 15 October 2026") any more. The page now says its compounded tirzepatide is "Prepared by licensed US compounding pharmacies" and states in capitals that compounded medications are not FDA-approved for safety, efficacy or quality.

## What Maximus is

Maximus is a privately held cash-pay telehealth platform positioned as a "performance medicine" company for men. The brand language ("performance medicine," "human potential," "make optimal your new normal") is positioned more toward the optimization end of the wellness spectrum than the medical-treatment end — closer to high-performance athletic medicine than to standard primary-care framing. The platform is **not publicly traded** and does not file with the SEC.

The company self-reports 50,000+ members — meaningfully smaller than Ro's 3M+ claim or Mochi's 500k+ claim, and orders of magnitude below Hims's 2.4M+.

The product breadth is unusual. Where every other provider in our set leads with weight loss (GLP-1) and treats testosterone as a sideline (or doesn't carry it at all), Maximus reverses the priority. **Testosterone is the primary category.** The platform offers four delivery formats — testosterone cream, injectable testosterone, oral testosterone, and enclomiphene capsules.

GLP-1 (compounded tirzepatide, plus brand-name GLP-1s such as Wegovy and Zepbound) is a substantial second category but secondary. Additional categories include a patent-pending **Oxytocin Calming Cream** marketed for mood, stress, and sleep; **growth hormone peptides** including sermorelin; **lab testing** (a 146-marker comprehensive panel and a 10-marker at-home testosterone test); **ED treatments** (vardenafil, tadalafil, sildenafil); and an "All-in-One Gel" for hair growth.

The CEO and Co-Founder is foregrounded across the site with the "Dr." honorific. The title rests on a PhD in Clinical Psychology — described as Harvard-educated and a former Assistant Clinical Professor of Psychiatry at UCSF School of Medicine. Technically correct for a PhD-holder, but bears foregrounding for patients: this is not an MD credential, and the executive is not a prescribing physician. The clinical-business leadership and the prescribing physician roles are distinct.

## Pricing — and the catch

Maximus publishes its GLP-1 and Oxytocin Calming Cream prices, but the full testosterone, peptide, ED, and lab matrices live behind the per-protocol pages and the onboarding flow. The homepage shows representative entry rates rather than complete ladders.

> Prices checked against Maximus's weight-loss, tirzepatide and oxytocin pages on 11 November 2026. Testosterone, peptide, ED and lab prices sit inside the per-protocol pages and the onboarding flow. Re-verification before signup recommended; we update this page when prices change.

**Weight loss (GLP-1)**

| Medication | Price | Format |
| --- | --- | --- |
| Tirzepatide, 2-month plan | **$249.99/mo** | Compounded SC injection |
| Tirzepatide, 4-month plan | **$219.99/mo** | Compounded SC injection |
| Tirzepatide, 6-month plan | **$199.99/mo** | Compounded SC injection |
| Tirzepatide, 12-month plan | **$149.99/mo** | Compounded SC injection |
| Foundayo (orforglipron) | **Starting at $199.99/mo** | Brand-name daily pill |
| Wegovy pill | **Starting at $249.99/mo** | Brand-name daily pill |
| Wegovy or Ozempic injection | **Starting at $349.99/mo** | Brand-name weekly injection |
| Zepbound | **Starting at $449.99/mo** | Brand-name weekly injection |
| Mounjaro | **Starting at $1,249.99/mo** | Brand-name weekly injection |

Compounded tirzepatide is sold only on these plans; there is no month-to-month option. The "$149.99/mo" on the tirzepatide page is the 12-month rate. Compounded semaglutide, listed from $149.99/mo when we first reviewed Maximus in June 2026, is no longer offered.

**Mood, stress, sleep**

| Product | Entry price |
| --- | --- |
| Oxytocin Calming Cream | **$99 for the first month, then $199/mo** (first-month price marked as a limited-time offer) — patent-pending transdermal formulation |

**Testosterone, growth hormone peptides, ED, lab testing**

Specific pricing for testosterone protocols (cream, injectable, oral, enclomiphene), growth hormone peptides (sermorelin and others), ED medications (vardenafil/tadalafil/sildenafil), and lab panels was not on the static homepage at the time of this review. Maximus shows them inside the onboarding flow.

**Insurance / FSA / HSA.** Maximus explicitly states it "doesn't require insurance" and operates on transparent direct-pay pricing. Insurance is not accepted. FSA/HSA acceptance is not advertised on the homepage; ask at signup. We saw no Klarna, Affirm or Afterpay option on its pages.

## How the process works

Maximus's funnel is broadly the cash-pay-telehealth template with two distinctive features.

**Online health questionnaire.** Detailed intake covering goals, history, and current medications.

**Online physician consultation.** A Maximus physician reviews the information 100% online and determines the appropriate protocol. The consultation model — synchronous, asynchronous, or hybrid — is not specified on the homepage; per-protocol pages and onboarding screens may clarify.

**Lab work from home (if needed).** Maximus operates a "deeper insights" lab layer through Maximus Labs (separate from the standard at-home testosterone test). The 146-marker comprehensive panel is offered as part of testosterone-protocol onboarding when clinically appropriate.

**Personalized protocol.** Medications, supplements, and "lifestyle guidance" shipped in discreet, secure packaging.

**Care team check-ins.** Track progress, doctor-led adjustments as needed.

**Discord community.** Maximus operates an official Discord (linked from the homepage) for community engagement. This is unusual in the medical-DTC space and reflects the platform's positioning toward the men's-optimization community rather than the standard primary-care framing.

Maximus does not publish an intake-to-shipment timeline.

## Does it work

Maximus's headline outcome visualizations — **"↑3.1× Free testosterone, 382 → 1180"** for testosterone and **"↓28% body fat over 18 months"** for weight loss — are presented in clinical-trial-style chart formats but are **not footnoted to any peer-reviewed source**. They are uncited company-marketing graphics. Under our editorial standards, claims of this kind are recorded as what the company says but not propagated as evidence.

The underlying evidence base for what Maximus's offerings can do exists in the peer-reviewed literature, just not in Maximus's own publications.

**Testosterone replacement therapy (general).** The most current cardiovascular-safety primary trial is [TRAVERSE](https://pubmed.ncbi.nlm.nih.gov/ "Source — Lincoff AM et al., TRAVERSE, NEJM 2023") (Lincoff AM et al., NEJM 2023), which assessed cardiovascular outcomes in middle-aged and older men receiving testosterone replacement. Standard testosterone-therapy literature also includes meta-analyses of muscle mass, bone density, mood, and sexual function endpoints. **FDA-approved branded testosterone products** include Depo-Testosterone (cypionate injection, NDA 085635, 1979), AndroGel (topical, NDA 021015, 2000), and KYZATREX (oral, NDA 215312, Marius Pharmaceuticals, 2022). The clinical evidence base for branded testosterone-replacement therapy is substantial.

**Enclomiphene as TRT alternative.** Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene is FDA-approved as Clomid for fertility treatment in women. Enclomiphene is **not FDA-approved** as a standalone therapy for any indication. Its use for elevating endogenous testosterone in men is **off-label** with preliminary, primarily early-phase trial evidence — there is no Phase 3 trial program demonstrating long-term cardiovascular safety or outcome equivalence to FDA-approved TRT. Maximus offers enclomiphene as part of its TRT menu but does not foreground the off-label status for patients.

**Compounded GLP-1.** For semaglutide and tirzepatide, the relevant Tier A trials are [STEP 1](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 "Source — Wilding JPH et al., STEP 1, NEJM 2021, PMID 33567185") (14.9% mean weight loss at 68 weeks) and [SURMOUNT-1](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 "Source — Jastreboff AM et al., SURMOUNT-1, NEJM 2022") (~20%+ at higher tirzepatide doses over 72 weeks). All studied **branded, FDA-approved** versions. Maximus dispenses compounded tirzepatide — same caveats apply as at other compounded-DTC providers in our set.

**Oxytocin Calming Cream.** This is the platform's most novel product. Oxytocin is an FDA-approved drug (Pitocin) for labor induction. **Transdermal compounded oxytocin formulations for mood, stress, and sleep are off-label and not FDA-reviewed for any of those indications.** The peer-reviewed evidence for intranasal oxytocin in social anxiety has been mixed (Quintana et al., Lancet Psychiatry meta-analyses); transdermal-delivery-specific evidence for mood/stress/sleep outcomes is sparse.

Maximus's outcome claims for the cream — improved happiness, sleep satisfaction, reduced anxiety, more sleep per night — are footnoted to a **Maximus-published whitepaper** ("A Novel Oxytocin Formulation for Mood, Stress, and Sleep") that meets all four exclusion criteria under our editorial standards (Maximus-employee authorship, study population on Maximus's own platform, no independent control, publication venue not peer-reviewed). We record this as a marketing observation; we do not propagate the outcome claims as evidence.

**Sermorelin and growth hormone peptides.** Sermorelin is not FDA-approved as a drug; it is commonly compounded for off-label growth hormone support. Peer-reviewed evidence for sermorelin in adults is limited — most published research is in pediatric growth hormone deficiency.

**PDE5 inhibitors (sildenafil, tadalafil, vardenafil).** FDA-approved and well-established.

## Safety and who should skip

**Testosterone replacement therapy** carries documented risks including erythrocytosis (elevated red blood cell mass), prostate hypertrophy, sleep apnea exacerbation, gynecomastia, and reduced fertility from suppression of endogenous testosterone production. Cardiovascular safety in middle-aged and older men was addressed in TRAVERSE, which found no significant increase in major adverse cardiovascular events vs. placebo. However, individual risk varies and ongoing monitoring through lab work is standard.

**Anastrozole** (an aromatase inhibitor included with most Maximus testosterone protocols) carries its own safety profile including reduced bone mineral density and lipid changes — appropriate monitoring is required.

**Enclomiphene** is off-label for testosterone elevation in men. Long-term safety data is limited.

**Compounded GLP-1** carries the same class-level risks as branded (GI side effects, pancreatitis, gallbladder problems, thyroid C-cell tumor boxed warning, pregnancy contraindication) plus the additional compounded-product quality concerns documented in FDA FAERS (elevated AE rates and potency errors).

**Compounded oxytocin (transdermal)** has limited safety profile data for the mood/stress/sleep use case. Standard hormonal medication precautions apply, but the specific transdermal-mood formulation Maximus dispenses is not the subject of any FDA-reviewed safety dataset.

Maximus operates a substantial lab-testing layer alongside the protocols, which is the right approach for testosterone management. The platform's focus on baseline labs before treatment and follow-up labs during treatment is medically appropriate, even if the company-stated outcome statistics built on top of those labs are not independently verifiable.

Anyone considering Maximus should be eyes-open about: the off-label status of enclomiphene as TRT, the experimental nature of the transdermal oxytocin cream for mood/stress, and the compounded status of the GLP-1 line.

## The compounding question

Maximus's exposure to the FDA's GLP-1 compounding regulatory squeeze parallels other compounded-DTC providers. The FDA timeline — semaglutide and tirzepatide removed from shortage (Dec 2024 / Feb 2025), 503A and 503B grace periods ending in April and May 2025, the 503B Bulks List exclusion proposal of April 2026, and the public-comment deadline of [29 June 2026](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list "Source — FDA press announcement, Apr 2026") (later [extended to 30 July 2026](https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal "Source — Federal Register, extension of comment period, 26 June 2026"); no final decision as of 7 October 2026) — applies to Maximus's compounded GLP-1 line.

On the marketing side of that same squeeze, Maximus is now also one of the named recipients in the FDA's [June 8, 2026 enforcement batch](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026 "Source — FDA Warning Letter MARCS-CMS 730095") against telehealth platforms selling compounded GLP-1s. The letter (MARCS-CMS 730095, signed by Matthew J. Lash, JD, Acting Director of the Office of Compounding Quality and Compliance) does not address Maximus's testosterone, oxytocin, sermorelin, or any non-GLP-1 product — it is narrowly about four phrases on the weight-loss page.

Two of the four ("Clinically studied ingredients," "Clinically studied to help patients…") implicate the company's habit of citing self-published whitepapers as if they were independent evidence — the exact pattern we already excluded under our editorial source-hierarchy rule for self-published studies. The third ("Proven to lose weight effectively") is the kind of unqualified efficacy claim that compounded products, by FDA's definition, cannot make.

The fourth ("FDA approved pharmacies") is the most common pattern in the entire June 8 batch: marketing copy on telehealth sites that conflates an outsourcing facility's voluntary FDA registration with actual FDA approval, which the FD&C Act does not establish for compounders.

The full analysis of the four claim patterns FDA cited across the batch is in our [news story](https://peptidewellnessusa.com/news/fda-warning-letters-compounded-glp-1-june-2026/).

Beyond GLP-1, Maximus is exposed to a different regulatory landscape that the other providers in our set don't share. **Testosterone is a Schedule III controlled substance.** Prescribing requires DEA registration. Compounded testosterone products are more regulated than compounded GLP-1, with state-pharmacy-board oversight on every batch. Maximus's compounded testosterone formats (cream, injection, oral) operate inside that framework.

**Enclomiphene is not FDA-approved as a drug.** Maximus's compounded enclomiphene capsules operate under the standard 503A compounding allowance for individualized prescriptions, but the underlying drug has no FDA-approved label for the use Maximus prescribes it for.

**Sermorelin** is also not FDA-approved as a drug for adult growth-hormone support; compounded for off-label use under standard 503A regulation.

**Oxytocin Calming Cream** is "patent-pending" per Maximus's own copy. A patent application is not the same as a granted patent. The formulation is also not FDA-approved for mood/stress/sleep indications.

Maximus's pharmacy partner language: *"We strictly partner with US-based, fully licensed compounding pharmacies that operate in compliance with rigorous USP standards for sterility and quality assurance. ... Active Pharmaceutical Ingredients exclusively from FDA-registered manufacturers."* This is consistent with 503A operation but does not foreclose 503B partnerships. Maximus does not say whether its partner pharmacies operate under 503A or 503B.

## The wider menu

Maximus's category breadth is broad but uneven across the categories. Selected detail:

| Category | Programs | Notes |
| --- | --- | --- |
| **Testosterone (primary)** | Testosterone Cream, Injectable Testosterone, Oral Testosterone, Enclomiphene | Four delivery formats. Pricing not on homepage. Lab testing typically required |
| Weight loss (GLP-1) | Tirzepatide ($149.99–$249.99/mo by plan length); brand-name Foundayo, Wegovy, Ozempic, Zepbound, Mounjaro (from $199.99/mo) | Tirzepatide compounded; others FDA-approved |
| Mood, stress, sleep | **Oxytocin Calming Cream** ($99 first month, then $199/mo) | Compounded transdermal; patent-pending; not FDA-approved for mood/stress/sleep |
| Growth hormone peptides | Sermorelin and others | Compounded; off-label for adult use |
| Lab testing | Comprehensive panel (up to 146 markers); at-home testosterone test (10 markers) | Multi-analyte |
| ED / Blood flow | Vardenafil, Tadalafil, Sildenafil | FDA-approved generics |
| Hair growth | All-in-One Gel (compounded combo) | Compounded |
| Prescription multivitamin | "Building Blocks" | Compounded supplement |

**The testosterone-cream-plus-enclomiphene fertility-preservation protocol** is one of Maximus's distinctive bets. Compounded topical testosterone combined with enclomiphene is marketed as a way to elevate testosterone while preserving endogenous production (and therefore fertility) — a meaningful selling point for younger men considering TRT. Maximus has published its own whitepaper on this protocol; per our standards, that whitepaper is excluded as evidence and is recorded only as a marketing observation. The underlying clinical rationale has academic precedent, but the specific Maximus protocol is not subject to independent peer-reviewed validation.

**The Oxytocin Calming Cream** is unusual in our provider set. Transdermal oxytocin formulations are not a commodity offering — most other DTC providers do not carry this. Whether the novelty maps to clinical efficacy is precisely the question the Maximus whitepaper purports to answer (and the question peer-reviewed literature has not yet answered).

## The advisory layer

Maximus publishes a named medical advisory team on the homepage and describes most of it as academic urologists.

The **CEO and Co-Founder** carries a PhD in Clinical Psychology (not an MD), as discussed in section 01. The remaining four advisors are described by Maximus as MDs. We cross-checked two of the four against the public [NPI Registry](https://npiregistry.cms.hhs.gov/ "Source — CMS National Provider Identifier Registry") on 10 June 2026 — both are individually registered and actively licensed. Maximus describes one as Chief of Andrology at Tulane Medical Center and the other as an Assistant Clinical Professor at Cedars-Sinai.

On 15 October 2026 we checked two more: the advisor Maximus describes as an Adjunct Associate Professor of Urology at UNC, and the advisor described as a hormone expert and author of *The Testosterone Syndrome*. Both are active in the registry. Maximus's home page now also lists a sixth figure, described as a "board-certified clinical hormone & peptide specialist" without a degree or a named board; with no degree, specialty or state to go on, we could not match that name to a single registry record.

For a testosterone-focused platform, named advisers who check out in the registry are a meaningful signal. The academic titles are Maximus's own description.

## Pros and cons

**Reading the third-party signals.** Maximus shows the conflict pattern familiar from the compounded-DTC set: Trustpilot positive (4.4/5 across 1,108 reviews, read 9 Nov 2026), BBB weaker (not accredited; B− rating per [the BBB profile](https://www.bbb.org/us/ca/santa-monica/profile/vitamins-and-supplements/maximus-tribe-1216-1000044380 "Source — Better Business Bureau profile, Maximus Tribe")). The sample size is smaller than at Henry, Mochi, or Hims, consistent with Maximus's self-stated 50k+ member count (smaller than the GLP-1-focused peers). BBB's profile was read on 14 October 2026.

**Pros.**

**Named advisory board that checks out.** Four advisers named by Maximus are active in the NPI Registry. Maximus describes three of them as urology faculty at Tulane, Cedars-Sinai and UNC.

**Four testosterone delivery formats** under one platform — cream, injectable, oral, and enclomiphene. Patients with different preferences and contraindications have options most competitors don't offer.

**Substantial lab testing layer** integrated with the testosterone protocol. The 146-marker comprehensive panel is unusual at this price point, and the testosterone-specific at-home test is appropriate for the category.

**Novel oxytocin transdermal product** — the only provider in our set offering this. Whether the novelty maps to clinical efficacy is unresolved, but the product itself is a distinctive bet.

**LegitScript certified** (seal ID 9646940).

**Cons and trade-offs.**

**BBB rates Maximus B−, and the company is not BBB-accredited.** Per [the BBB profile](https://www.bbb.org/us/ca/santa-monica/profile/vitamins-and-supplements/maximus-tribe-1216-1000044380 "Source — Better Business Bureau profile, Maximus Tribe, read 14 October 2026"), Maximus Tribe is not a BBB Accredited Business and carries a B− rating, with 19 complaints in the last three years and a 1.32-out-of-5 customer review average across 19 reviews.

**Self-published whitepaper layer is the primary evidence base for proprietary protocols.** Maximus has published 5+ whitepapers on its own protocols (Oral TRT liver safety, Enclomiphene protocol, Topical Testosterone + Enclomiphene for fertility preservation, Oxytocin formulation). All meet the four exclusion criteria under our editorial standards. We record their existence as marketing observations; we do not propagate their numbers.

**Outcome visualizations are uncited.** "↑3.1× Free testosterone" and "↓28% body fat over 18 months" appear in chart-style formats suggestive of clinical-trial results, with no underlying peer-reviewed citation, no cohort size disclosure, and no timeframe specification beyond "over 18 months." Treat as marketing.

**Enclomiphene as TRT is off-label** and not foregrounded as such for patients. Long-term safety data is limited.

**Oxytocin Calming Cream is not FDA-approved** for mood/stress/sleep and rests its outcome claims on the Maximus-authored whitepaper.

**The "Dr." honorific on the CEO's name may be misread as a physician credential.** Maximus's CEO and Co-Founder holds a PhD in Clinical Psychology, not an MD. The "Dr." title is technically correct but the distinction warrants foregrounding for prospective patients.

**Full pricing matrix is not public.** Testosterone, peptide, ED, and lab prices appear only on per-protocol pages or inside the onboarding flow.

**Compounded medications are not FDA-approved,** and tirzepatide/semaglutide availability is regulation-sensitive (the FDA has not yet decided on its April 2026 proposal to exclude these drugs from the 503B Bulks List).

**One listed specialist gives no degree or board.** The home page describes one adviser as a "board-certified clinical hormone & peptide specialist" without naming a degree or a certifying board.

## Who should choose — and skip

Maximus makes the most sense for the **men's-optimization-focused patient** who wants testosterone-replacement therapy with a named advisory board behind it, who is comfortable with off-label use of enclomiphene as a fertility-preserving TRT alternative, and who wants a serious lab-testing layer underpinning the protocol. It fits patients who specifically want compounded testosterone in multiple delivery formats; who are interested in trying the novel transdermal oxytocin cream and understand it's experimental for mood/stress; and who value a named, checkable advisory board more than a large advertising or public-market presence.

Skip it if you want only FDA-approved therapies — Maximus's compounded GLP-1, compounded testosterone, compounded enclomiphene, sermorelin, and compounded oxytocin are all off-label or non-FDA-approved at the product level. Skip it if you weight peer-reviewed evidence heavily — Maximus's marketing leans on self-published whitepapers and uncited outcome visualizations rather than peer-reviewed primary trials.

Skip it if you want detailed transparency on the compounded GLP-1 line — Maximus's compounded tirzepatide is priced lower than most branded options but lacks the manufacturer-direct supply story Hims and Ro have. And skip it if the "Dr." honorific on the CEO's name reads differently to you once you know the title rests on a PhD in Clinical Psychology rather than an MD.

## Maximus vs the alternatives

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Maximus's position is clear at this level.

Against the **other men's-focused DTC operators** (Hims), Maximus has a much deeper testosterone-format menu (Hims's testosterone surface is enclomiphene-only; Maximus offers four formats) and an advisory board Maximus describes as academic urologists. Hims counters with NYSE-listed transparency and FDA-approved branded GLP-1. Against the **broad branded operators** (Ro), Maximus is narrower-category but has more clinical depth in testosterone specifically.

Against the **compounded-DTC operators** (TeleZenMD, Henry, Mochi, TrimRx), Maximus's GLP-1 line is comparable on pricing but the testosterone-focus is a meaningful differentiator. Against **Henry Meds specifically on TRT**, Henry includes the FDA-approved oral KYZATREX option that Maximus does not carry; Maximus has the deeper compounded format range.

The clearest case for Maximus over any of those alternatives is wanting a testosterone-focused platform with a named advisory board, multiple format choices, and a serious lab-testing layer — knowing the trade-offs around off-label enclomiphene, the self-published whitepaper evidence base, and the compounded GLP-1 line.

## Who makes the medication

From Maximus’s public pages, read Sep 24, 2026.

|  |  |
| --- | --- |
| Pharmacy | Not named on its public pages |
| Prescriber | Not named on its public pages |

Its about page explains how it selects "US-based, fully licensed compounding pharmacies" and names none. The about page names advisers, but does not say they prescribe; the terms refer to "Maximus Medical Group Practices" without naming a legal entity.

Read from: [Maximus About](https://www.maximustribe.com/about-us), [Maximus terms of use](https://www.maximustribe.com/terms-of-use).

How the other providers we cover answer the same question: [which telehealth providers name their pharmacy](https://peptidewellnessusa.com/learn/which-providers-name-their-pharmacy/).

## Frequently asked

### Is Maximus legit?

Maximus is a privately held U.S. cash-pay telehealth platform. It is LegitScript-certified (seal ID 9646940). Four of the named medical advisors are verified active in the public NPI Registry; Maximus describes three of them as academic urologists (Tulane, Cedars-Sinai, UNC). The CEO holds a PhD in Clinical Psychology, not an MD. The platform offers a substantial lab-testing layer integrated with its testosterone protocols, which is medically appropriate.

### How much does Maximus cost?

As of 11 November 2026, compounded tirzepatide costs $249.99 a month on a 2-month plan, down to $149.99 a month on a 12-month plan; there is no month-to-month option. The prices had been $50 a month lower on every plan from mid-October until this reading, and are now back at the rates Maximus set on 2 October. Brand-name GLP-1s start at $199.99 a month. Oxytocin Calming Cream costs $99 for the first month, then $199 a month. Testosterone, growth hormone peptide, ED, and lab prices appear only on per-protocol pages or inside the onboarding flow.

### Does Maximus take insurance?

No. Maximus is cash-pay only. FSA/HSA acceptance is not foregrounded on the homepage.

### Is the "Dr." on the CEO's name a physician credential?

No. Maximus's CEO and Co-Founder holds a PhD in Clinical Psychology — described as Harvard-educated and a former Assistant Clinical Professor of Psychiatry at UCSF. The "Dr." title is technically correct for a PhD-holder, but the CEO is not an MD and not a prescribing physician.

### Is enclomiphene FDA-approved?

No, not as a standalone therapy. Enclomiphene is the trans-isomer of clomiphene citrate (Clomid, FDA-approved for fertility in women). Enclomiphene as a testosterone-elevation therapy in men is off-label. Maximus offers it as part of the TRT menu under the standard 503A compounding allowance.

### Is the Oxytocin Calming Cream FDA-approved?

No. Oxytocin (as Pitocin) is FDA-approved for labor induction. Maximus's transdermal compounded oxytocin formulation for mood, stress, and sleep is off-label. The product is described as "patent-pending."

### Does Maximus offer FDA-approved testosterone (like KYZATREX)?

No. Maximus's four testosterone formats — cream, injectable, oral, enclomiphene — are all either compounded or off-label. Patients specifically wanting FDA-approved oral testosterone (KYZATREX, Marius Pharmaceuticals, NDA 215312) should look at Henry Meds, which carries it at $179/month.

### What lab testing does Maximus offer?

A comprehensive panel of up to 146 markers and a 10-marker at-home testosterone test. The lab layer is integrated with the testosterone protocol — baseline labs before treatment and follow-up labs during treatment. This is medically appropriate for testosterone management.

## Methodology & disclaimers

**How we reviewed this.** Pricing, programs, and medical-leadership details were pulled directly from Maximus's public homepage and per-category nav menus in June 2026. Specific pricing for testosterone, peptides, ED, and lab testing was not on the static homepage; Maximus shows it inside the onboarding flow.

Prescriber verification was conducted independently against the public [NPI Registry](https://npiregistry.cms.hhs.gov/ "Source — CMS National Provider Identifier Registry") for four Maximus-named advisors (three it describes as urology faculty at Tulane, Cedars-Sinai and UNC, and the hormone-book author; checked 10 June and 15 October 2026), all individually registered and active. A sixth figure listed on the home page gives no degree and could not be matched to one record. The CEO and Co-Founder holds a PhD in Clinical Psychology, not an MD, so NPI is not applicable.

Clinical claims in this review are anchored to peer-reviewed primary trials (STEP 1, SURMOUNT-1, TRAVERSE, plus FDA-approved testosterone benchmarks) and FDA primary sources; we do not propagate the "3.1× free testosterone," "28% body fat reduction," or oxytocin-cream outcome claims as evidence — they are uncited or footnoted only to Maximus-published whitepapers that meet our exclusion criteria for company-affiliated self-published studies.

**Editorial independence.** PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Maximus.

> Editorial note: Informational only — not medical advice. Compounded medications aren't FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded pharmaceuticals. Off-label use of enclomiphene as TRT and transdermal oxytocin for mood/stress/sleep carry distinct regulatory and clinical profiles. Testosterone-replacement, weight-loss, and hormone decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.